Merck & Co’s – known as MSD outside of the US and Canada – Welireg (belzutifan) has been conditionally approved by the ...

Life science company Epitopea, rooted in Cambridge UK and both Montreal and Quebec in Canada, has clinched a licensing deal ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, announces a license and research collaboration agreement with MSD (tradename ...

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, ...

Epitopea has inked a license and research collaboration with Merck to discover new tumor-specific antigens from so-called ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral ...

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

Laboratories can now save valuable time, reduce costs, and improve accuracy with Metrohm’s 948 Continuous IC Module, CEP—the ...

Rahway: Merck, known as MSD outside of the United States and Canada, has received conditional approval from the European ...

Merck’s Welireg receives European approval for two indications: Rahway, New Jersey Wednesday, February 19, 2025, 10:00 Hrs [IST] Merck, known as MSD outside of the United States ...